ScripVera Therapeutics reported 36-week results on June 2 from the ORIGIN Phase III clinical trial of its B-cell modulator atacicept in the treatment of immunoglobulin A nephropathy (IgAN) in adults, showi
In VivoAt SynBioBeta 2025, In Vivo spoke with several executives leading companies at the cutting edge of synthetic biology and techbio. These conversations revealed not just technological breakthroughs, b
ScripBefore life sciences companies reported first-quarter earnings, a jump in sales might have been expected as companies and patients stocked up ahead of tariffs. But in the event, this was less pronounc
Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet